Kinase Inhibitor News and Research

RSS
A protein kinase inhibitor is a type of enzyme inhibitor that specifically blocks the action of one or more protein kinases.
FDA approves LORBRENA for treatment of patients with ALK-positive metastatic NSCLC

FDA approves LORBRENA for treatment of patients with ALK-positive metastatic NSCLC

Study offers new hope to patients with rare brain cancer

Study offers new hope to patients with rare brain cancer

Study shows potential of avelumab plus axitinib as new treatment option for patients with advanced RCC

Study shows potential of avelumab plus axitinib as new treatment option for patients with advanced RCC

Study: Erlotinib improves progression-free survival in EGFR mutated NSCLC

Study: Erlotinib improves progression-free survival in EGFR mutated NSCLC

Study: Sarcoma patients poorly informed about risk of interactions with anti-cancer drugs

Study: Sarcoma patients poorly informed about risk of interactions with anti-cancer drugs

NCCN adds COPIKTRA capsules to NCCN Guidelines for follicular lymphoma

NCCN adds COPIKTRA capsules to NCCN Guidelines for follicular lymphoma

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC

Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC

Survey: Physicians need more information to assess impact of NSCLC treatment sequencing

Survey: Physicians need more information to assess impact of NSCLC treatment sequencing

ADCETRIS drug receives approval in Japan as frontline treatment option for Hodgkin lymphoma

ADCETRIS drug receives approval in Japan as frontline treatment option for Hodgkin lymphoma

China NMPA approves LENVIMA for treatment of unresectable hepatocellular carcinoma

China NMPA approves LENVIMA for treatment of unresectable hepatocellular carcinoma

CHMP adopts positive opinion of Takeda’s ALUNBRIG for treatment of ALK+ non-small cell lung cancer

CHMP adopts positive opinion of Takeda’s ALUNBRIG for treatment of ALK+ non-small cell lung cancer

NCCN updates Clinical Practice Guidelines to include new recommendations for CABOMETYX tablets

NCCN updates Clinical Practice Guidelines to include new recommendations for CABOMETYX tablets

BeiGene collaborates with SpringWorks to evaluate new combinational therapy for solid tumors

BeiGene collaborates with SpringWorks to evaluate new combinational therapy for solid tumors

New combination approach may help crush resistance to treatment in lung cancer patients

New combination approach may help crush resistance to treatment in lung cancer patients

Inflection Biosciences' dual mechanism inhibitor shows promise as treatment for CLL

Inflection Biosciences' dual mechanism inhibitor shows promise as treatment for CLL

Researchers use x-ray crystallography to reveal how curcumin inhibits cancer

Researchers use x-ray crystallography to reveal how curcumin inhibits cancer

Ocular Therapeutix resubmits NDA for DEXTENZA

Ocular Therapeutix resubmits NDA for DEXTENZA

Coffee and the heart – four strong cups a day is beneficial finds study

Coffee and the heart – four strong cups a day is beneficial finds study

Experts propose new solutions to increase benefit, affordability of targeted cancer medicines

Experts propose new solutions to increase benefit, affordability of targeted cancer medicines